At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 298 enrolled
Drug / intervention
olaparibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy and Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have a Confirmed Genetic BRCA 1 and/or BRCA2 Mutation
In Brief
A Phase 2 clinical trial evaluating olaparib for Ovarian and 4 related conditions. Completed, enrolled 298 participants across 14 sites in 6 countries.
Detailed Summary
To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian, Breast, Prostate, Pancreatic, Advanced Tumours
CountriesAustralia, Germany, Israel, Spain, Sweden, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2010
First PostedMar 2010
Primary CompletionJul 2012
Study CompletionAug 2024
TodayJul 2026
First PostedMar 2, 2010
Enrollment StartFeb 21, 2010
Primary CompletionJul 31, 2012
Study CompletionAug 12, 2024
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 16.3 years ago
Interventions
olaparibdrug
Tablets Oral BID